Prof. José Luis González Larriba

Complutense University of Madrid, Madrid, Spain

Hospital Clínico San Carlos, Madrid, Spain

Email: jlgonz02@ucm.es

Qualifications

2017 Full Professor, Complutense University of Madrid, Madrid, Spain

2005 Head of Thoracic, Urologic Tumors and Melanoma, Hospital Clínico San Carlos, Madrid, Spain

1993 Ph.D., Complutense University of Madrid, Madrid, Spain

1978 M.D., Complutense University of Madrid, Madrid, Spain

Publications (Selected)

1. Vicente-Valor, J., Aguado, C., Mateos, M., et al. (2026). Microbiota biomarkers as predictors on immunotherapy response in patients with advanced non-small cell lung cancer. Lung Cancer, 216, Article 109381.
2. Molina-Alejandre, M., Martínez-Toledo, C., Sierra-Rodero, B., et al. (2026). Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer. Biomarker Research, 14(1), Article 49.
3. Sierra-Rodero, B., Gil-González, A., Molina-Alejandre, M., et al. (2026). Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer. Clinical Cancer Research, 32(8), 1499–1512.
4. Provencio, M., Serna-Blasco, R., Nadal, E., et al. (2026). Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer. Clinical Cancer Research, 32(4), 748–755.
5. Serna-Blasco, R., Medina, K., Sala, M. A., et al. (2025). KRAS Mutation Status in Non-Small Cell Lung Cancer Distribution Across Occupational Categories. Chest, 168(6), 1528–1543.
6. Sureda, M. B., Gonzalez-Larriba, J. L., Marti, A. M., et al. (2025). Cost-effectiveness analysis of perioperative chemoimmunotherapy in stage III non-small cell lung cancer: Analysis of role of postoperative nivolumab. Annals of Oncology, 36(Suppl. 2), S1041.
7. Carcereny, E., Cobo, M., Calvo, V., et al. (2025). Impact of Immunotherapy on Overall Survival in Advanced Non-Small Cell Lung Cancer: A Real-World Evidence Analysis. Journal of Thoracic Oncology, 20(10_suppl), P1.11.37.
8. Massuti, B., Nadal, E., Gonzalez-Larriba, J. L., et al. (2025). Pharmacoeconomic Analysis of NADIM 2 Trial: Cost-Effectiveness of Perioperative Chemo-Immunotherapy in Resectable Stage III NSCLC. Journal of Thoracic Oncology, 20(10_suppl), MA06.03.
9. Mediavilla-Medel, P., Nadal, E., Gonzalez-Larriba, J. L., et al. (2025). Metabolomic Analysis Identifies Histamine as a Key Predictive Factor for Perioperative Chemoimmunotherapy in NADIM II Trial. Journal of Thoracic Oncology, 20(10_suppl), MA01.03.
10. Provencio, M., Bernabé, R., Nadal, E., et al. (2025). Adjuvant Chemotherapy (CT) vs CT-immunotherapy for R0 Stage IB-IIIA NSCLC Patients (NADIM ADJUVANT): a Randomized, Phase 3 Trial. Journal of Thoracic Oncology, 20(10_suppl), PL03.10.
11. Ospina-Serrano, A. V., González-Larriba, J. L., Nadal, E., et al. (2025). Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement. Translational Lung Cancer Research, 14(9).
12. Provencio, M., Cobo, M., Rodriguez-Abreu, D., et al. (2025). Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain. The Lancet Regional Health - Europe, 56, Article 101402.
13. García, L. F., Conde, E., Hernandez, S., et al. (2026). PD-L1 expression scoring using artificial intelligence algorithms in non-small cell lung cancer harbouring ROS1 fusions: potential clinical-biological significance. Clinical and Translational Oncology, 28(2), 484–493.
14. Massuti, B., Nadal, E., Gonzalez-Larriba, J. L., et al. (2025). Pharmacoeconomic analysis of perioperative chemo-immunotherapy in resectable stage III non small cell lung cancer (NSCLC): Survival time cost-efficacy based on NADIM 2 trial. Journal of Clinical Oncology, 43(16_suppl), Article e23141.
15. Serna-Blasco, R., Mediavilla-Medel, P., Medinab, K., et al. (2025). Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study. Lung Cancer, 204, Article 108550.
16. Sierra-Rodero, B., Martínez-Toledo, C., Molina-Alejandre, M., et al. (2025). B cells mediate antitumor immune response and predict pathological response in locally advanced NSCLC patients treated with perioperative chemoimmunotherapy (NADIM trials). Cancer Research, 85(8_suppl), 4542.
17. Abreu, D. R., Lazaro, M. E., Piqueras, M. M. L. B., et al. (2025). Osimertinib for patients with EGFRm non-small cell lung cancer: Analysis of the locally advanced/metastatic cohort (OSIREAL study). Journal of Thoracic Oncology, 20(3_suppl), 63P.
18. Serna-Blasco, R., Nadal, E., Gonzalez-Larriba, J. L., et al. (2025). Prognostic Value of minimal residual disease in the NADIM II trial. Journal of Thoracic Oncology, 20(3_suppl), 210P.
19. Vicente-Valor, J., de la Rosa, C. A., Cabezas, M. P., et al. (2025). Microbiota biomarkers as predictors of immunotherapy response in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology, 20(3_suppl), 361P.
20. Antoñanzas, M., Amman, M., Jarabo, J. R., et al. (2024). Long Term Follow-up of Two Decades Experience with Neoadyuvant Chemotherapy in Resectable Non Small Cell Lung Cancer. Journal of Thoracic Oncology, 19(10_suppl), S569–S570

Profile Details
https://produccioncientifica.ucm.es/investigadores/145714/detalle
https://www.researchgate.net/profile/Jose-Luis-Gonzalez-Larriba

WOS ResearcherID: G-6177-2016